MediciNova (NASDAQ:MNOV – Get Free Report) will likely be posting its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.05 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
MediciNova (NASDAQ:MNOV – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.07 million. On average, analysts expect MediciNova to post ($0.25) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.
MediciNova Stock Performance
NASDAQ:MNOV opened at $1.47 on Tuesday. The firm has a 50-day moving average price of $1.79 and a two-hundred day moving average price of $1.51. MediciNova has a twelve month low of $1.22 and a twelve month high of $3.90.
Insider Buying and Selling at MediciNova
In related news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $2.70, for a total transaction of $1,728,000.00. Following the transaction, the insider owned 4,862,047 shares of the company’s stock, valued at approximately $13,127,526.90. This represents a 11.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 14.00% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
MNOV has been the topic of several research reports. HC Wainwright reiterated a “buy” rating on shares of MediciNova in a research report on Tuesday, September 29th. Weiss Ratings upgraded MediciNova from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. Finally, Roth Capital began coverage on MediciNova in a report on Thursday, September 17th. They issued a “buy” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.
Check Out Our Latest Stock Report on MNOV
About MediciNova
MediciNova, Inc (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions.
Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.
Further Reading
- Five stocks we like better than MediciNova
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
